CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Harpoon Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Harpoon Therapeutics Inc
611 Gateway Boulevard, Suite 400
Phone: (650) 443-7400p:650 443-7400 SOUTH SAN FRANCISCO, CA  94080  United States Fax: (302) 655-5049f:302 655-5049

This company was Merged or Acquired on 3/11/2024.
This company ceased filing statements with the SEC on 3/21/2024.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company. The Company is engaged in the developing a T cell engager that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. The Company is developing a pipeline of T cell engagers using its TriTACs technology, focused on the treatment of solid tumors and hematologic malignancies. It has also nominated its clinical candidate using its ProTriTAC platform, a prodrug version of its TriTAC platform.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/202312/31/2022YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Non-Executive Chairman of the Board, Independent Director Scott D.Myers 57 10/1/2021 8/1/2018
President, Chief Executive Officer, Secretary, Director Julie M.Eastland 59 1/1/2022 10/1/2018
Principal Financial Officer, Principal Accounting Officer, Corporate Controller Frank J.Lanza 52 9/19/2022 9/19/2022
8 additional Officers and Directors records available in full report.

General Information
Number of Employees: 53 (As of 10/31/2023)
Outstanding Shares: 21,397,205 (As of 2/6/2024)
Shareholders: 17
Stock Exchange: NASD
Federal Tax Id: 473458693
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 18, 2024